Mesenchymal stem cells offer novel treatment approach for Crohn's disease fistula

September 14, 2017

New Rochelle, NY, Sept. 14, 2017--A growing body of clinical evidence shows that transplantation of a patient's own mesenchymal stem cells (MSCs) to achieve a cure and prevent recurrent of Crohn's disease-related fistula can be a safe and effective addition to surgery. A comprehensive review of the latest studies of MSC transplantation for Crohn's fistula and a comparison of MSC versus hematopoietic stem cell (HSC) transplantation is published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Human Gene Therapy website until October 14, 2017.

Fistulas, especially anorectal fistulas, are a common complication of the inflammatory intestinal disorder Crohn's disease. Coauthors Xiao-mei Zhang, Yu-jing Zhang, Wei Wang, Yu-Quan Wei, and Hong-xin Deng, Sichuan University, Chengdu, China, discuss the clinical research supporting the potential for MSC transplantation to improve surgical outcomes, lower the risk of fistula recurrence, and enhance patients' quality of life. In the article entitled "Mesenchymal Stem Cells to Treat Crohn's Disease with Fistula," the authors examine the unique advantages of MSCs, including ease of collection, low immunogenicity when using a patient's own cells for transplant, and the immunoregulatory activity of MSCs.

"Crohn's disease continues to be a major burden on human health despite newer immunomodulatory therapies, and Crohn's-related fistulas are a particularly intractable problem for many patients," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. "This paper demonstrates promising results with mesenchymal stem cells as a novel regenerative medicine approach to this complication. The work could ultimately result in major benefits to many individuals suffering with this disease."
-end-
About the Journal

Human Gene Therapy the Official Journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Led by Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its companion journals, Human Gene Therapy Methods , published bimonthly and focused on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development," published quarterly, features data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of contents for all three publications and a free sample issue may be viewed on the Human Gene Therapy website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Nucleic Acid Therapeutics, Tissue Engineering, Stem Cells and Development, and Cellular Reprogramming. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 http://www.liebertpub.comPhone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101

Mary Ann Liebert, Inc./Genetic Engineering News

Related Mesenchymal Stem Cells Articles from Brightsurf:

More selective elimination of leukemia stem cells and blood stem cells
Hematopoietic stem cells from a healthy donor can help patients suffering from acute leukemia.

Novel method produces life-saving T cells from mesenchymal stromal cells
A new study released today in STEM CELLS suggests for the first time that regulatory T-cells (Treg) induced by mesenchymal stromal cells can yield an abundant replacement for naturally occurring T-cells, which are vital in protecting the body from infection.

Computer simulations visualize how DNA is recognized to convert cells into stem cells
Researchers of the Hubrecht Institute (KNAW - The Netherlands) and the Max Planck Institute in M√ľnster (Germany) have revealed how an essential protein helps to activate genomic DNA during the conversion of regular adult human cells into stem cells.

Dr. Jekyll, Mr. Hyde: Study reveals healing mesenchymal cells morph and destroy muscles in models of spinal cord injury, ALS and spinal muscular atrophy
Scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP), in collaboration with the Fondazione Santa Lucia IRCCS in Rome, have discovered a new disease-specific role in FAP cells in the development of muscle tissue wasting, indicating a potential new avenue for treating motor neuron diseases including spinal cord injury, ALS and spinal muscular atrophy.

Researchers develop a new method for turning skin cells into pluripotent stem cells
Researchers at the University of Helsinki, Finland, and Karolinska Institutet, Sweden, have for the first time succeeded in converting human skin cells into pluripotent stem cells by activating the cell's own genes.

Researchers identify mesenchymal stem cells (MSCs) in human arteries
Mount Sinai researchers identified, in situ and in vivo, adventitial CD90+ (a protein used as a marker for a variety of stem cells) and mesenchymal stem cells (MSCs) in human arteries for the first time.

In mice, stem cells seem to work in fighting obesity! What about stem cells in humans?
This release aims to summarize the available literature in regard to the effect of Mesenchymal Stem Cells transplantation on obesity and related comorbidities from the animal model.

Application of mesenchymal stem cells stimulates nervous tissue regeneration
The research team used model spinal cord injuries in rats for their purposes.

Unraveling how mesenchymal stem cells from gum tissue accelerate wound healing
Researchers at the University of Pennsylvania set out to determine whether and how gum-derived stem cells play a role in accelerated wound healing.

Mesenchymal stem cell therapy: Holding promise for feline inflammatory diseases
Stem cell therapy is acknowledged as having great potential for the treatment of a variety of diseases in both people and animals.

Read More: Mesenchymal Stem Cells News and Mesenchymal Stem Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.